New vaccine trial aims to train body to fight returning prostate cancer
NCT ID NCT05617040
Summary
This early-stage trial tested a new vaccine called VTP-850 for men whose prostate cancer has started to return after initial surgery or radiation. The goal was to see if the vaccine is safe and if it can train the body's immune system to fight the cancer, which would be shown by a drop in PSA levels. The study was small and ended early, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Cornell University
New York, New York, 10065-4805, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.